Photo taken from: Al-Ola A Abdallah/X
Feb 12, 2024, 01:59
Al-Ola A Abdallah: Did the FDA Oncology make a big mistake by withdrawing Belantamab?
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, made the following post on X:
“It’s the BCMA Era for myeloma:
Cilta-Cel vs SOC (DPd/PVd): 12 months PFS 76% vs 49%
Ide-Cel vs SOC: mPFS 13.4 vs 4.4 months
Belantamab/Vd vs DVd: mPFS 37 vs 13.4 months
Did the FDA Oncology make a big mistake by withdrawing Belantamab?”
Source: Al-Ola A Abdallah/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14